Services on Demand
Journal
Article
Indicators
Cited by SciELO
Access statistics
Related links
Similars in SciELO
Share
Ginecología y obstetricia de México
Print version ISSN 0300-9041
Abstract
GONZALEZ-MARINO, Mario Arturo. Serous ovarian cancer. Report of 14 cases and review of the bibliography. Ginecol. obstet. Méx. [online]. 2020, vol.88, n.7, pp.442-449. Epub Sep 24, 2021. ISSN 0300-9041. https://doi.org/10.24245/gom.v88i7.3208.
OBJECTIVE:
To describe the epidemiological, clinical, laboratory, surgical medical management and pathology characteristics in a series of 14 patients with serous ovarian carcinoma in a highly complex hospital and review of the literature in order to update the concepts.
MATERIALS AND METHODS:
Retrospective and descriptive case series study of a patient with serous ovarian cancer confirmed by pathology. The patients were studied in a highly complex general hospital between 2013 and 2016. Study variables: Epidemiological, clinical, laboratory surgical medical treatment, comorbidities, and pathology. Narrative review of the bibliography corresponding to information related to the evaluated variables.
RESULTS:
Fourteen women between the ages of 50 and 80 were diagnosed, 3 with a history of hysterectomy and 1 with tubal ligation. Histological diagnosis: 10 with high-grade serous tumor, 2 moderately differentiated, 1 low-grade serous and one not classified. Surgical procedures: hysterectomy, bilateral salpinges-oophorectomy, lymphadenectomy, omentectomy in 8 cases. They classified into states: IV in 6, 3 IIIB, 2 IC, 1 IIIC and 1 IB. Treatment 10 women with carboplatin and paclitaxel. Review 2227 articles were found, 41 sectioned.
CONCLUSIONS:
Serous ovarian carcinoma is currently classified as low and high grade (more frequent and aggressive). This type was the most frequent, the risk factors found by the reduced number do not allow conclusions to be drawn.
Keywords : Serous Ovarian Cancer; Hysterectomy; Tubal Ligation; Serous Tumor; Hysterectomy bilateral; Oophorectomy; Lymphadenectomy; Carboplatin; Paclitaxel; Risk Factors.